Invasive Pneumokokken-Erkrankungen in Deutschland im Zeitalter der Pneumokokken-Konjugat-Impfung

Zusammenfassung

Hintergrund: Pneumokokken sind weltweit eine der häufigsten bakteriellen Ursachen von Pneumonie, Sepsis und Meningitis.

Methodik: Das Nationale Referenzzentrum für Streptokokken (NRZS) am Institut für Medizinische Mikrobiologie der Uniklinik RWTH Aachen führt seit 1992 Studien über invasive Pneumokokken-Erkrankungen (IPE) durch. Diesem Bericht liegen Daten der IPE-Fällen von Juli 1992–Juni 2013 bei Erwachsenen und von Juli 1997–Juni 2013 bei Kindern zugrunde.

Ergebnisse: Der prozentuale Anteil von Infektionen durch im 7-valenten Impfstoff enthaltene Serotypen lag von 1997–2006 bei Kindern ≤ 23 Monate bei ca. 65 %. Seit dem Beginn des Impfprogramms 2006 sank er kontinuierlich auf < 5 % 2012 /2013. Aber auch bei den nicht geimpften Erwachsenen sank der Anteil von ursprünglich etwa 40–45 % (1992–2006) auf ca. 8 % (2012 /2013), was als Herdenschutzeffekt bezeichnet wird. Die Resistenzrate gegen Penicillin G lag bei Kindern durchgehend unter 4 %, bei Erwachsenen unter 2,5 %. Die Makrolid-Resistenz ist seit 2005 /2006 recht kontinuierlich gefallen und lag zuletzt bei ca. 5 % (Kinder) bzw. 8 % (Erwachsene).

Folgerung: Der kontinuierliche Rückgang der Impfstoff-Serotypen sowie rückläufige IPE-Inzidenzen seit dem Beginn des Impfprogramms bei Kindern belegen den Erfolg der Pneumokokken-Konjugat-Impfung.

Abstract

Background: Pneumococci remain a major cause of bacterial pneumonia, sepsis and meningitis globally.

Methods: The German National Reference Center for Streptococci at the Institute for Medical Microbiology of the University Hospital RWTH Aachen, Germany, has carried out surveillance studies on invasive pneumococcal disease (IPD) since 1992. This report is based on IPD-cases from adults and children, received between July 1992 and June 2013 and July 1997 and June 2013 respectively.

Results: From 1997–2006 the proportion of infections among children ≤ 23 months of age with serotypes included in the 7-valent vaccine was about 65 %. Since the start of childhood vaccination in 2006 the percentage has continuously decreased, reaching < 5 % in 2012 /2013. Also among adults, for whom conjugate vaccination was not indicated, this percentage decreased from 40–45 % in 1992–2006 to about 8 % in 2012 /2013. This phenomenon is denoted as herd protection. The resistance rate against Penicillin G remained under 4 % among children and under 2.5 % among adults over the whole study period. Since 2005 /2006 macrolide resistance levels have decreased to about 5 % among children and 8 % among adults.

Conclusion: The continuous decrease of vaccine serotypes as well as the decreasing IPD incidence since the beginning of childhood vaccination document the success of pneumococcal conjugate vaccination.

Schlüsselwörter

Streptococcus pneumoniae - Serotypen - Pneumokokken-Konjugat-Impfung - Penicillin-Resistenz - Makrolid-Resistenz - invasive Pneumokokken-Erkrankungen - Deutschland

Keywords

Streptococcus pneumoniae - serotypes - pneumococcal conjugate vaccination - penicillin resistance - macrolide resistance - invasive pneumococcal disease - Germany

• Literatur

• 1 Arguedas A, Kvaerner K, Liese J et al. Otitis media across nine countries: disease burden and management. Int J Pediatr Otorhinolaryngol 2010; 74: 1419-1424
• 2 Brueggemann AB, Griffiths DT, Meats E et al. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 2003; 187: 1424-1432
• 3 Brueggemann AB, Peto TE, Crook DW et al. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004; 190: 1203-1211
• 4 Butler JC, Shapiro ED, Carlone GM. Pneumococcal vaccines: history, current status, and future directions. Am J Med 1999; 107: 69S-76S
• 5 Byington CL, Samore MH, Stoddard GJ et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005; 41: 21-29
• 6 CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54: 893-897
• 7 Choi YH, Jit M, Gay N et al. 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?. PLoS One 2011; 6: e26190
• 8 Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. Wayne, PA: 2008
• 9 De Lencastre H, Kristinsson KG, Brito-Avo A et al. Carriage of respiratory tract pathogens and molecular epidemiology of Streptococcus pneumoniae colonization in healthy children attending day care centers in Lisbon, Portugal. Microb Drug Resist 1999; 5: 19-29
• 10 Gemeinsamer Bundesausschuss. Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Schutzimpfungs-Richtlinie: Umsetzung der STIKO-Empfehlungen. Juli 2012. http://www.g-ba.de/downloads/40-268-2088/2012-10-18_SI-RL_STIKO-Juli2012_TrG.pdf Accessed: 02.05.2014
• 11 Harboe ZB, Thomsen RW, Riis A et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009; 6: e1000081
• 12 Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007; 196: 1346-1354
• 13 Imöhl M, Reinert RR, Mutscher C et al. Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008. BMC Microbiol 2010; 10: 299
• 14 Imöhl M, Reinert RR, van der Linden M. Serotype-specific penicillin resistance of Streptococcus pneumoniae in Germany from 1992 to 2008. Int J Med Microbiol 2010; 300: 324-330
• 15 Jansen AG, Rodenburg GD, van der Ende A et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009; 49: e23-29
• 16 Kellner J. Update on the success of the pneumococcal conjugate vaccine. Paediatr Child Health 2011; 16: 233-240
• 17 Kupronis BA, Richards CL, Whitney CG. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc 2003; 51: 1520-1525
• 18 Lynch 3rd JP, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010; 16: 217-225
• 19 Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41
• 20 Pletz MW, Maus U, Hohlfeld JM et al. Pneumokokkenimpfung: Konjugatimpfstoff induziert Herdenimmunitat und reduziert Antibiotikaresistenz. Dtsch Med Wochenschr 2008; 133: 358-362
• 21 Pletz MW, Maus U, Krug N et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008; 32: 199-206
• 22 Pletz MW, von Baum H, van der Linden M et al. Epidemiologie, Klinik und Verlauf der Pneumokokkenpneumonie – Daten aus CAPNETZ. Pneumologie 2012; 66: 470-475
• 23 Reinert RR. Streptokokken-Infektionen – Aktuelle Aspekte zur Diagnostik, Prophylaxe und Therapie. Bremen: Uni-Med Verlag; 2007
• 24 Reinert RR, Ringelstein A, van der Linden M et al. Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe. J Clin Microbiol 2005; 43: 1294-1300
• 25 Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285: 1729-1735
• 26 Rückinger S, van der Linden M, Reinert RR et al. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 2009; 27: 4136-4141
• 27 Ruggeberg JU, Ketteler K, MacKenzie CR et al. Blood culture sampling rates at a German pediatric university hospital and incidence of invasive pneumococcal disease. Infection 2004; 32: 78-81
• 28 Sächsische Impfkommission. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen . Stand: 01.01.2014. www.slaek.de/de/03/36impfen/pdf/E1_2014.pdf Letzter Zugriff: 02.05.2014
• 29 Sleeman KL, Griffiths D, Shackley F et al. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis 2006; 194: 682-688
• 30 Ständige Impfkommission (STIKO). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut / Stand: Juli 2001. Epidemiologisches Bulletin 2001; 28: 203-218
• 31 Ständige Impfkommission (STIKO). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut / Stand: Juli 2006. Epidemiologisches Bulletin 2006; 30: 235-254
• 32 Ständige Impfkommission (STIKO). Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut / Stand: August 2013. Epidemiologisches Bulletin 2013; 34: 313-344
• 33 van der Linden M, Weiss S, Falkenhorst G et al. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine 2012; 30: 5880-5885
• 34 Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011; 378: 1962-1973
• 35 Welte T. Pneumonie – Geschichtliche Entwicklung, Status quo und Ausblick. Pneumologie 2010; 64: 560-566